Description
Apixaban Film-Coated Tablets (2.5 mg / 5 mg)
Healthy Inc is a specialized global supplier and exporter of advanced cardiology, hematology, and targeted cardiovascular therapeutics. We provide ultra-high-purity, kinetically optimized Apixaban Tablets, manufactured in WHO–GMP certified, high-precision oral solid dosage facilities. This “Direct Factor Xa Inhibitor” is a premium strategic export to cardiology hospitals, stroke units, and government health ministries, serving as the globally mandated intervention for stroke prevention in non-valvular Atrial Fibrillation (AF) and the treatment of Deep Vein Thrombosis (DVT).
Product Overview
This formulation operates as a biochemical “Clot-Blocker.” Apixaban is engineered to target a specific point in the blood-clotting process, ensuring the blood remains fluid without the unpredictable fluctuations associated with older anticoagulants.
Mechanism 1 (Direct Factor Xa Inhibition): Apixaban is a highly selective, reversible inhibitor of Factor Xa. Factor Xa is the critical “bottleneck” in the coagulation cascade where the intrinsic and extrinsic pathways meet to produce Thrombin. By blocking Factor Xa, Apixaban physically prevents the conversion of Prothrombin to Thrombin.
Mechanism 2 (Fibrin Thrombus Prevention): By stopping the production of Thrombin, the drug prevents the formation of Fibrin, the “mesh” that holds blood clots together. This significantly reduces the risk of clots traveling to the brain (Stroke) or lungs (Pulmonary Embolism).
Mechanism 3 (The Predictable Advantage): Unlike Warfarin, Apixaban does not require routine blood monitoring (INR tests) and has very few food interactions. It provides a stable anticoagulant effect from the first dose, making it much easier for patients to manage long-term.
Product Composition & Strength
We supply this product as a Precision-Blended, High-Bioavailability Tablet, packed in high-barrier Alu-Alu blister strips to ensure the stability of the active API.
| Active Ingredient | Strength | Primary Clinical Function |
| Apixaban USP/Ph.Eur. | 2.5 mg | The Dose-Reduction Unit: Used for patients with specific risk factors (Age ≥80, Weight ≤60kg, or high Creatinine) to minimize bleeding. |
| Apixaban USP/Ph.Eur. | 5 mg | The Therapeutic Anchor: The standard maintenance dose for stroke prevention in Atrial Fibrillation and DVT treatment. |
| Excipients | Proprietary Matrix | Rapid-Dissolution System: Engineered to ensure a consistent $T_{max}$ of approx. 3 to 4 hours for reliable protection. |
Technical & Logistics Specifications
HS Code: 3004.90.99 (Medicaments containing other active substances – Cardiovascular/Anticoagulant)
CAS Number: 503612-47-3 (Apixaban)
Dosage Form: Film-Coated Tablet
Packaging: Alu-Alu Blisters. Protects the API from environmental humidity; our moisture-lock packaging ensures 24-month stability in Zone IVb tropical climates.
Manufacturing Authority & Compliance
API Purity Excellence: Our manufacturing process focuses on absolute chemical purity to ensure the Factor Xa selectivity remains exact, providing the predictable clinical response required for high-risk cardiac patients.
Bioequivalence Integrity: We provide comprehensive dissolution data to prove our generic matches the pharmacokinetic profile of the innovator brand (Eliquis), ensuring a seamless transition for chronic patients.
Primary Indications
Cardiology: Reduction of the risk of stroke and systemic embolism in patients with non-valvular Atrial Fibrillation.
Hematology: Treatment and prevention of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).
Orthopedics: Prophylaxis of DVT following hip or knee replacement surgery.
Dosage & Administration
Atrial Fibrillation: Standard dose is 5 mg twice daily.
DVT/PE Treatment: Typically started at 10 mg twice daily for 7 days, followed by 5 mg twice daily.
Administration: Can be taken with or without food. Tablets can be crushed and suspended in water if necessary for patients with swallowing difficulties.
Safety Warning: Bleeding Risk. As with all anticoagulants, Apixaban increases the risk of serious bleeding. Black Box Warning: Premature discontinuation increases the risk of thrombotic events (clots). Avoid use in patients with prosthetic heart valves or severe hepatic impairment.
Global Export & Contract Manufacturing
Healthy Inc is a premier Cardiovascular Pharmaceutical Exporter in India. As a verified Medicine Supplier in Mumbai, we offer flexible Third Party Manufacturing (Contract Manufacturing) for next-generation DOACs. Whether you are a Stroke Center Network in Africa or a B2B Pharma Marketplace partner in the CIS, we ensure secure, WHO-GMP compliant delivery.
Reviews
There are no reviews yet.